Share
  • Facebook
  • Twitter
  • Linked In
  • Google+
back top
Vericel (VCEL): Revenue Growth Fueled by Three Cellular Therapies

1300 members from 70 countries Join ICRS

News

Vericel (Nasdaq: VCEL), a specialty biologics company with three approved cellular therapy products on the market might still be underappreciated by investors after its recent run?

Vericel (VCEL): Revenue Growth Fueled by Three Cellular Therapies

Vericel (VCEL): Revenue Growth Fueled by Three Cellular Therapies

01/09/2017

CENTENNIAL, Colo., Jan. 19, 2016 /PRNewswire-USNewswire/ — AlloSource®, one of the nation’s largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, was awarded U.S. Patent Number 9,186,253, titled Cartilage mosaic compositions and methods, for its new cartilage repair allograft, ProChondrix® Cartilage Restoration Matrix.

AlloSource’s New Cartilage Repair Product, ProChondrix, Receives Patent

AlloSource’s New Cartilage Repair Product, ProChondrix, Receives Patent

20/01/2016

Press Release: Piramal Enterprises announces sale of its Canada-based cartilage repair product, BST-CarGel® to Smith & Nephew Montreal, January 12, 2016: Piramal Enterprises Limited (‘PEL’, NSE: PEL, BSE: 500302) today announces the sale of BST-CarGel® from Piramal Healthcare (Canada) Limited, based in Montreal, Canada to Smith & Nephew (NYSE:SNN;LSE:SN), the global medical technology business. BST-CarGel® is a first-line cartilage repair product used along with microfracture and other bone marrow stimulation techniques for the initial treatment of most sizes of focal cartilage tears. Through this transaction, an affiliate of Smith & Nephew plc will acquire ownership of all product and intellectual property assets related to BST-CarGel.

Press Release: Piramal Canada sells BST Cargel to S&N

Press Release: Piramal Canada sells BST Cargel to S&N

14/01/2016